A phase 1b clinical trial to determine the safety, tolerability and immunogenicity of simian adenovirus and poxvirus vectored vaccines against a Mycobacterium avium complex subspecies in patients with active Crohn's disease.

Saved in:
Bibliographic Details
Title: A phase 1b clinical trial to determine the safety, tolerability and immunogenicity of simian adenovirus and poxvirus vectored vaccines against a Mycobacterium avium complex subspecies in patients with active Crohn's disease.
Authors: Sanderson J; Guy's and St Thomas' Hospitals NHS Foundation Trust, Great Maze Pond, London SE1 9RT, UK., Aboagye J; The Jenner Institute, ORCRB, University of Oxford, Oxford, OX3 7DQ, UK., Makinson R; The Jenner Institute, ORCRB, University of Oxford, Oxford, OX3 7DQ, UK., Rapi K; The Jenner Institute, ORCRB, University of Oxford, Oxford, OX3 7DQ, UK., Provstgaard-Morys S; The Jenner Institute, ORCRB, University of Oxford, Oxford, OX3 7DQ, UK., Stockdale L; The Jenner Institute, ORCRB, University of Oxford, Oxford, OX3 7DQ, UK., Alison Lawrie; The Jenner Institute, ORCRB, University of Oxford, Oxford, OX3 7DQ, UK., Lanigan I; Guy's and St Thomas' Hospitals NHS Foundation Trust, Great Maze Pond, London SE1 9RT, UK., Halim N; Guy's and St Thomas' Hospitals NHS Foundation Trust, Great Maze Pond, London SE1 9RT, UK., Douiri A; Kings College London, Great Maze Pond, London SE1 1UL, UK., Greenlay E; Kings College London, Great Maze Pond, London SE1 1UL, UK., Malek R; Kings College London, Great Maze Pond, London SE1 1UL, UK., Gray E; Kings College London, Great Maze Pond, London SE1 1UL, UK., West L; Kings College London, Great Maze Pond, London SE1 1UL, UK., El Oulidi F; HAV Vaccines Limited, Np-105, Icentre, Howard Way, Newport Pagnell, Milton Keynes MK16 9PY, UK., Cross PI; HAV Vaccines Limited, Np-105, Icentre, Howard Way, Newport Pagnell, Milton Keynes MK16 9PY, UK. Electronic address: paul@pauliancross.com., Stallibrass M; HAV Vaccines Limited, Np-105, Icentre, Howard Way, Newport Pagnell, Milton Keynes MK16 9PY, UK., Gilbert SC; The Jenner Institute, ORCRB, University of Oxford, Oxford, OX3 7DQ, UK., Hill AVS; The Jenner Institute, ORCRB, University of Oxford, Oxford, OX3 7DQ, UK., Ewer KJ; The Jenner Institute, ORCRB, University of Oxford, Oxford, OX3 7DQ, UK.
Source: EBioMedicine [EBioMedicine] 2025 Mar; Vol. 113, pp. 105570. Date of Electronic Publication: 2025 Feb 07.
Publication Type: Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial
Journal Info: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101647039 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3964 (Electronic) Linking ISSN: 23523964 NLM ISO Abbreviation: EBioMedicine Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2352-3964
DOI:10.1016/j.ebiom.2025.105570